Showing 20 of 60 recruiting trials for “diffuse-large-b-cell-lymphoma”
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RecruitingNCT05831865 ↗
Frontline of ASCT in High-risk DLBCL
Study of SGR-1505 in Mature B-Cell Neoplasms
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Genotype-guided Treatment in DLBCL
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Enrolling by InvitationNCT05690191 ↗
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
👨⚕️ Bingzong LI, Second Affiliated Hospital of Soochow University📍 1 site📅 Started Jun 2021View details ↗
DALY II USA/ MB-CART2019.1 for DLBCL
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
👨⚕️ Alvaro J Alencar, Alliance for Clinical Trials in Oncology📍 54 sites📅 Started May 2021View details ↗
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
👨⚕️ Francesco Merli, Dott., Reggio Emilia - Azienda Unitа Sanitaria Locale-IRCCS📍 49 sites📅 Started Mar 2021View details ↗
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Enrolling by InvitationNCT04491721 ↗
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
👨⚕️ Yuankai Shi, Doctor, Chinese Academy of Medical Sciences📍 1 site📅 Started Jul 2020View details ↗
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
👨⚕️ Wei Xu, M.D., Ph.D, The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)📍 1 site📅 Started Jun 2020View details ↗
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
👨⚕️ Yuankai SHI, Prof, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 23 sites📅 Started Jan 2020View details ↗
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
👨⚕️ Jayant Sastri Goda, M.D, Professor,Tata Memorial Centre📍 1 site📅 Started Nov 2016View details ↗
← PreviousPage 3 of 3
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →